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Mycosis fungoides (MF) is the most common type
of cutaneous T-cell lymphoma (CTCL).1 Immuno-
stimulatory approaches, such as interferon adminis-
tration, are well established in the treatment of CTCL.2
In the last years, several new antibodies that enhance
the immune system activity have entered the field of
cancer immunotherapy. Ipilimumab (a cytotoxic T-
lymphocyte antigene4 [CTLA4]- blocking antibody,
Yervoy, Bristol-Myers Squibb, Princeton, NJ) was the
first one of its class to receive an approval for
treatment of melanoma.3 Whether ipilimumab might
be effective in CTCL is not known.We describe a case
of complete remission of cutaneous MF during
ipilimumab treatment for advanced melanoma.CASE REPORT
A 44-year-old man presented in 1992 with scaly
plaques on the trunk and extremities with histopa-
thology of parapsoriasis. In 2002, 2 biopsies in 2
separate medical centers showed MF, stage IA. He
was treated with ultraviolet B phototherapy until
complete remission, but the MF recurred clinically
and histopathologically 14 months later. The patient
was followed up but chose to avoid further inter-
vention. In 2011 he had melanoma on the scalp
diagnosed for the first time, Breslow 4.2 mm,
without ulceration andwith negative sentinel lymph
node biopsy, stage IIb. He underwent wide local
excision and a sentinel lymph node biopsy. One
year later, he had regional in-transit melanoma
recurrence requiring further surgery. Eventually
in 2013, he presented with biopsy-proven metas-
tasis in the right parotid gland and left cervical
lymph node, without any other metastasis accord-
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BRAF mutation was negative. MF patches and
plaques were present on his chest and arms. The
patient started treatment with ipilimumab in January
2014, given every 21 days for a maximum of 4
treatments. After the third treatment, all the cuta-
neous MF lesions disappeared. Positron emission
tomographyecomputed tomography after the
fourth and last ipilimumab treatment showed mixed
response, with a new fluorodeoxyglucose-avid
palpable lymph node in the left side of the neck.
Second-line treatment with pembrolizumab (anti-
program deathe1eblocked antibody, Keytruda,
Merck, Sharp Dohme Corp, Whitehouse Station,
NJ) was started with partial response. Currently, the
patient is still in complete remission from his MF.
DISCUSSION
CTLA-4 is a negative costimulatory molecule
that inhibits T-cell activation by binding to CD86 in
the immunologic synapse, and its expression is
highly regulated. A significant increase in CTLA-4
expression was seen in malignant T cells from
patients with MF, while exhibiting a correlation
between higher expression and the grade of the
disease.4 Also, inhibition of proteasome function in
normal T cells with bortezomib caused sustained
expression of CTLA-4 in normal CD41 T cells,
mimicking the expression pattern observed in
Sezary syndrome.5 This finding suggests that target-
ing this pathway may be beneficial in CTLA-JAAD Case Reports 2015;1:99-100.
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possible explanation for the regression of MF in
our case was that CTLA-4 blockade decreased
regulatory T-cell activity, which enhanced the anti-
tumoral immunologic activity against MF.
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